GLP1R and type 2 diabetes mellitus: Human studies, despite some controversial effects regarding the incretin’s effects in subclinical atherosclerosis, have shown a significant reduction in cardiovascular events using GLP-1 agonists in patients with diabetes mellitus type 2.